Table 2:
eGFR slopes for participants with eGFR 15–90 mL/min/1.73 m2.
| N | Mean | SD | Median (range) | |
|---|---|---|---|---|
| Baseline (at IgAN237-1) | ||||
| eGFR (mL/min/1.73 m2) | 74 | 48.4 | 19.4 | 47.9 (16.6 to 86.5) |
| eGFRTotal-slope (mL/min/1.73 m2/year) | 70 | –0.2 | 3.5 | –0.5 (–8.0 to 13.8) |
| eGFRChron-slope (mL/min/1.73 m2/year) | 70 | –0.9 | 3.4 | –0.8 (–8.9 to 16.7) |
| eGFRProsp-slope (mL/min/1.73 m2/year) | 70 | –1.4 | 7.1 | –1.1 (–19.8 to 24.1) |
| eGFR180days-slope (mL/min/1.73 m2/year) | 70 | –3.2 | 6.8 | –2.8 (–21.8 to 20.5) |
| Follow-up (at IgAN237-2) | ||||
| eGFR (mL/min/1.73 m2) | 57 | 47.9 | 20.4 | 45.6 (16.7 to 89.2) |
| eGFRTotal-slope (mL/min/1.73 m2/year) | 55 | 0.3 | 3.7 | –0.5 (–7.0 to 13.8) |
| eGFRChron-slope (mL/min/1.73 m2/year) | 55 | –0.8 | 3.5 | –0.8 (–8.1 to 16.7) |
| eGFRProsp-slope (mL/min/1.73 m2/year) | 53 | 2.6 | 14.4 | 0.3 (–42.5 to 62.2) |
| eGFR180days-slope (mL/min/1.73 m2/year) | 53 | –0.1 | 8.5 | –0.5 (–22.2 to 18.2) |
N = number of patients with available analyses; SD = standard deviation.